Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Ajax Health, the medical device portfolio management company newly formed by KKR and Aisling Capital, led a $45 million round for Advanced Cardiac Therapeutics and the next-generation ablation catheter it’s developing.
Earlier today the private equity giants launched tapped Spirox chairman & CEO Duke Rohlen to lead Ajax Health. Rohlen, the former president of FoxHollow Technologies and the founder & former chief executive of CV Ingenuity, is also CEO at ACT. Read more
Ophthalmic device developer LensGen said today it closed a $21 million Series A financing round to support its Juvene accommodating intraocular lens.
The financing round was led by the corporate venture investment arm of Hoya Group and was joined by Relativity Healthcare Partners, the Irvine, Calif.-based company said. Read more
Private equity giants KKR and Aisling Capital said today that they’re launching a company to manage their portfolio of medical device companies called Ajax Health, tapping Spirox chairman & CEO Duke Rohlen to lead it.
Rohlen is the former president of FoxHollow Technologies and the founder & former chief executive of CV Ingenuity. Read more
Axonics Modulation Technologies said today that it put nearly $15 million into its coffers as it readies a pivotal study later this year for its sacral nerve modulation technology in treating overactive bladder syndrome.
The Irvine, Calif.-based company said it hopes to add another $15.5 million to the $14.5 million it pulled in from its Series C round, which involved all of its major backers including Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, Legend Capital, NeoMed Management and “a select group of private individuals.” Read more
Becton Dickinson beat the consensus forecast with its fiscal 2nd-quarter earnings and said it plans to shift the business model for its U.S. medication management business.
The Franklin Lakes, N.J.-based healthcare giant posted profits of $344 million, or $1.58 per share, on sales of $2.97 billion for the 3 months ended March 31, boosting the bottom line by 1.8% despite a -3.2% sales decline. BD said cited the divestiture of the controlling stake in its respiratory solutions business for the top-line reversal. Read more